Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Helenalin: a multifaceted sesquiterpene lactone with diverse biological activities-an integrative pharmacological and computational evidence.

Created on 28 Jul 2026

Authors

Iqra Farzeen, Zunaira Jaan, Maryam Batool, Muhammad Muzammil Nazir, Derya Karatas Yeni, Muhammad Umar Ijaz, Asma Ashraf

Published in

Naunyn-Schmiedeberg's archives of pharmacology. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Helenalin, a naturally occurring sesquiterpene lactone derived primarily from Arnica montana, has emerged as a promising multitarget therapeutic agent due to its diverse anti-inflammatory, antioxidant, cytotoxic, and antimicrobial activities. The review summarized the pharmacological spectrum and molecular mechanisms underlying helenalin bioactivity. Helenalin exerts anticancer activities by regulating key oncogenic signaling, especially, NF-κB and STAT3/MYC pathway. Helenalin demonstrated Nrf2 antioxidant pathway activation and muted P2X7R-dependent inflammation in osteoarthritis models. It was also found to have antimicrobial activity and was effective in melting the redox and quorum sensing in the pathogens, which were interesting to use in the drug-resistant infections. ADMET predictions support the good drug likeness, pharmacokinetics, and oral bioavailability, and it satisfies the Lipinski Rule of Five. The network pharmacological and GO/KEGG enrichment analyses indicated the implication of helenalin in cancer and inflammation -related pathways. Molecular docking also showed strong binding with COX-1, Bcl-2, and hub target proteins having docking scores of - 9.2 to 11.3, respectively, which confirmed its potential as a pharmacological agent. The learning of this multifaceted pharmacology profile together with the tools of systems biology, however, establishes helenalin as an attractive lead compound towards the development of novel anticancer, anti-inflammatory, antiarthritic, antioxidant, antiviral, antibacterial, and antiangiogenic agents. Its therapeutic index should be further confirmed using future translational research.

PMID:
42517879
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement